Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.

Revenue(Q1, 2017)

$2.8 B

Market capitalization(2017-08-18)

$59.8 B

Training Provided, no. of people(FY, 2016)

40 K

Company Growth (employees)

Type

Public

Cambridge, US

Founded

1978

Size (employees)

7,400 (est)

Website

biogen.com

Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People at Biogen

Michel Vounatsos

CEO

Biogen Office Locations

Biogen has an office in Cambridge

Cambridge, US (HQ)

225 Binney St

Biogen Data and Metrics

Biogen Financial Metrics

Biogen's revenue was reported to be $2.8 b in Q1, 2017

Summary

USD

Biogen's current market capitalization is $59.8 b.

Source: Company Filings

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	6.9 b	9.7 b	10.8 b	11.4 b
Revenue growth, %		40%	11%	6%
R&D expense				(2 b)
General and administrative expense				(1.9 b)
Operating expense total				(3.9 b)
EBIT			4.9 b	5.2 b
EBIT margin, %			45%	45%
Income tax expense			1.2 b	1.2 b
Net Income	1.9 b	2.9 b	3.6 b	3.7 b

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Revenue	2.4 b	2.5 b	2.6 b	2.6 b	2.8 b	2.7 b	2.9 b	3 b	2.8 b
R&D expense	447.3 m	417.2 m	460.5 m	490.7 m	519.9 m	437.3 m	473.1 m	529 m	423.4 m
General and administrative expense	576.6 m	570.4 m	560.4 m	491.9 m	477.8 m	497.3 m	492.4 m	462.7 m	499.1 m
Operating expense total	1 b	987.6 m	1 b	982.6 m	997.7 m	934.6 m	965.5 m	991.7 m	922.5 m
EBIT	988.7 m	1.2 b	1.1 b	1.2 b	1.4 b	1.4 b	1.5 b	1.4 b	1 b
EBIT margin, %	41%	46%	44%	48%	49%	51%	50%	48%	36%
Income tax expense	268.5 m	274.8 m	281.9 m	292.5 m	330.1 m	356.4 m	353.6 m	337 m	239.2 m
Net Income	723.1 m	856.1 m	820.2 m	924.8 m	1 b	969.2 m	1 b	1 b	747.5 m

Source: Company Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	602.6 m	1.2 b	1.3 b	2.3 b
Accounts Receivable	824.4 m	1.3 b	1.2 b	1.4 b
Inventories	659 m	804 m	893.4 m	1 b
Current Assets	3.2 b	4.7 b	6.7 b	8.7 b
PP&E	1.8 b	1.8 b	2.2 b	2.5 b
Goodwill	1.2 b	1.8 b	2.7 b	3.7 b
Total Assets	11.9 b	14.3 b	19.5 b	22.9 b
Accounts Payable	219.9 m	229.2 m	267.4 m	279.8 m
Total Debt		1.2 b
Current Liabilities	1.8 b	2.2 b	2.6 b	3.4 b
Total Liabilities				10.7 b
Additional Paid-in Capital	4 b	4.2 b
Retained Earnings	6.3 b	9.3 b	12.2 b	15.1 b
Total Equity	8.6 b	10.8 b	9.4 b	12.1 b
Debt to Equity Ratio		0.1 x
Debt to Assets Ratio		0.1 x
Financial Leverage	1.4 x	1.3 x	2.1 x	1.9 x

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	863.2 m	1.2 b	1.5 b	1.3 b	4.1 b	1.1 b	1.4 b	2.1 b	924 m
Accounts Receivable	1 b	1.1 b	1.4 b	1.3 b	1.3 b	1.4 b	1.3 b	1.5 b	1.5 b
Inventories	715.9 m	753.1 m	825.3 m	865.7 m	918.9 m	964.6 m	996.4 m	1 b	921.6 m
Current Assets	3.9 b	4.4 b	5.3 b	5.6 b	9.3 b	7.2 b	7.4 b	8.1 b	6.9 b
PP&E	1.8 b	1.7 b	1.7 b	1.8 b	2 b	2.3 b	2.3 b	2.4 b	2.6 b
Goodwill	1.4 b	1.5 b	1.8 b	2.2 b	2.4 b	2.9 b	3.2 b	3.4 b	3.6 b
Total Assets	12.9 b	13.7 b	15.2 b	16.8 b	20.7 b	20.7 b	21.5 b	22.1 b	21.2 b
Accounts Payable	224.9 m	233.6 m	236.1 m	282.7 m	251.2 m	271.3 m	225.9 m	274 m	316.4 m
Current Liabilities	1.9 b	1.9 b	1.9 b	2.6 b	2.6 b	2.8 b	2.5 b	2.5 b	3 b
Additional Paid-in Capital	4.1 b	4.2 b	4.2 b	4.3 b	1.3 b	18.4 m	69.1 m
Retained Earnings	7.5 b	8.4 b	10.1 b	11 b	12 b	13.2 b	14.2 b	15 b	14.8 b
Total Equity	9.6 b	10.4 b	11.7 b	12.6 b	10.6 b	10.3 b	11.4 b	12.1 b	11.5 b
Financial Leverage	1.4 x	1.3 x	1.3 x	1.3 x	2 x	2 x	1.9 x	1.8 x	1.8 x

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	1.9 b	2.9 b	3.6 b	3.7 b
Depreciation and Amortization		688.2 m	600.4 m	682.7 m
Accounts Receivable	(130 m)	(510 m)	29 m	(241.4 m)
Inventories	(240 m)	(190 m)	(170 m)	(165.6 m)
Purchases of PP&E	(246.3 m)	(287.8 m)	(643 m)	(616.1 m)
Cash From Investing Activities	(1.6 b)	(1.5 b)	(4.6 b)	(2.5 b)
Cash From Financing Activities	(716.5 m)	(755.9 m)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	723.1 m	856.1 m	820.2 m	924.8 m	1 b	969.2 m	1 b	1 b	747.5 m
Accounts Receivable				1.3 b	1.3 b	1.4 b	1.3 b	1.5 b	1.5 b
Inventories				865.7 m	918.9 m	964.6 m	996.4 m	1 b	921.6 m
Accounts Payable				282.7 m	251.2 m	271.3 m	225.9 m	274 m	316.4 m

Ratios

USD	Y, 2017
Revenue/Employee	379.8 k
Financial Leverage	1.8 x

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016

	FY, 2016
Training Provided, no. of people	40 k
Phase III Trials	2
Phase II Trials	10
Phase I Trials	4

Source: SEC Filings

Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Market Position of Biogen

Competitors

Ironwood Pharmaceuticals

Health - Public

Compare competitors

Traffic Overview of Biogen

Biogen Online and Social Media Presence

Biogen News and Updates

December 20, 2016

Here’s Why Investors Weren’t Excited About Biogen’s New CEO

Biogen shares dropped as much as 4.6% on news of his appointment Monday.

September 03, 2016

Biogen Drug Shows Early Promise against Alzheimer’s Disease

Early results suggest a treatment for root causes, not just symptoms.

August 04, 2016

Biogen not pursuing a sale: source

(Reuters) - U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.

August 02, 2016

Biogen Shares Are Spiking On Rumors of a Mega-Deal With Its Rivals

Both Merck and Allergan are reportedly exploring a buyout.

Biogen

Company Growth (employees)

Key People at Biogen

Michel Vounatsos

Biogen Office Locations

Biogen Data and Metrics

Biogen Financial Metrics

Summary

Revenue (Q1, 2017)

Net income (Q1, 2017)

EBIT (Q1, 2017)

Market capitalization (18-Aug-2017)

Cash (31-Mar-2017)

Income Statement

Revenue

Revenue growth, %

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Income tax expense

Net Income

Revenue

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Income tax expense

Net Income

Balance Sheet

Cash

Accounts Receivable

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Total Debt

Current Liabilities

Total Liabilities

Additional Paid-in Capital

Retained Earnings

Total Equity

Debt to Equity Ratio

Debt to Assets Ratio

Financial Leverage

Cash

Accounts Receivable

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Current Liabilities

Additional Paid-in Capital

Retained Earnings

Total Equity

Financial Leverage

Cash Flow

Net Income

Depreciation and Amortization

Accounts Receivable

Inventories

Purchases of PP&E

Cash From Investing Activities

Cash From Financing Activities

Net Income

Accounts Receivable

Inventories

Accounts Payable

Ratios

Revenue/Employee

Financial Leverage

Biogen Operating Metrics

Training Provided, no. of people

Phase III Trials